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Abstract
Introduction: Transgenic overexpression of amyloid precursor protein (APP) genes that are either entirely human in
sequence or have humanized Aβ sequences can produce Alzheimer-type amyloidosis in mice, provided the transgenes
also encode mutations linked to familial Alzheimer’s Disease (FAD). Although transgenic mice have been produced that
overexpress wild-type mouse APP, no mice have been generated that express mouse APP with FAD mutations. Here we
describe two different versions of such mice that produce amyloid deposits consisting of entirely of mouse Aβ peptides.
One line of mice co-expresses mouse APP-Swedish (moAPPswe) with a human presenilin exon-9 deleted variant (PS1dE9)
and another line expresses mouse APP-Swedish/Indiana (APPsi) using tetracycline-regulated vectors (tet.moAPPsi).
Results: Both lines of mice that produce mouse Aβ develop amyloid deposits, with the moAPPswe/PS1dE9
micedeveloping extracellular compact, cored, neuritic deposits that primarily localize to white matter tracts andmeningial
layers, whereas the tet.moAPPsi mice developed extracellular diffuse cortical/hippocampal deposits distributed
throughout the parenchyma.
Conclusions: These findings demonstrate that murine Aβ peptides have the capacity to produce amyloid deposits that
are morphologically similar to deposits found in human AD provided the murine APP gene harbors mutations linked to
human FAD.
Introduction
Mutations in the amino acid sequence of the amyloid
precursor protein (APP) influence its cleavage by three
types of endo-proteases termed α, β, and γ-secretase
[8, 16]. Studies of APP processing by the enzyme
BACE1 have demonstrated that this enzyme, which is re-
sponsible for the cleavage event at the amino terminus of
Aβ, can cleave APP to produce two possible major amino
terminal sites, termed +1 and +11 (Fig. 1). For wild-type
APP sequence, BACE 1 generally cleaves APP at the +11
site, and after cleavage by γ-secretase, Aβ peptides 11–40
and 11–42 are produced [6]. A third enzyme, termed α-
secretase, cleaves APP within the Aβ peptide sequence to
produce peptides such as Aβ17-40 and 17–42 (for review
see [8, 16]). Importantly, Aβ11-40/42 and 17–40/42 pep-
tides are generally not found as significant components of
amyloid plaque lesions that characterize human AD
[13, 28]. The major Aβ peptide found in mature
neuritic plaques of human AD is Aβ1-42 [19, 30].
Mutations in APP that cause early-onset AD can in-
fluence cleavage of APP by either BACE1, γ-secretase,
or α-secretase so that a greater percentage of Aβ1-42
peptides are generated by these processes [for review
see [8, 16]. Thus, the early-onset of AD in patients
harboring mutations in APP is thought to be due to
the accelerated deposition of amyloid, which initiates
a cascade of pathogenic events to produce full
spectrum of AD symptoms [17].
In the much more common occurrence of sporadic
AD, which is pathologically characterized by the pres-
ence of amyloid deposits and tau pathology, mutations
in APP are not found and instead it has been suggested
that some aspect of aging changes the dynamics of Aβ
production or clearance to initiate disease. Amyloid de-
posits similar to human AD have been described in
many species of aged animals including non-human
* Correspondence: drb1@ufl.edu
1Center for Translational Research in Neurodegenerative Disease, University
of Florida, Gainesville, FL 32610, USA
2McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA
Full list of author information is available at the end of the article
© 2015 Xu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Xu et al. Acta Neuropathologica Communications  (2015) 3:72 
DOI 10.1186/s40478-015-0252-9
primates, dogs, and bears [39]. However, aged rodents
(mouse or rat) do not spontaneously develop amyloid
deposits. The human and murine amyloid precursor
proteins (APP) differ at three amino acid residues within
the Aβ peptide sequence (5, 10, and 13) (Fig. 1). These
differences have been reported to modulate the binding
of metal ions [18], which can influence fibrillogenesis of
Aβ peptides in vitro [1]. Additionally, cleavage of mouse
APP by mouse BACE1 largely produces Aβ11-40/42 in-
stead of the 1–40/42 peptides [6]. These attributes of the
murine Aβ peptide sequence appear to diminish the po-
tential for aged mice to spontaneously develop amyloid
deposits.
The capacity for murine Aβ to produce amyloid de-
posits appears to be limited even in aged mice. There
have been reports of intracellular accumulations of
granular Aβ immunoreactivity in the senescence acceler-
ated strains of mice (SAMP8) (reviewed in [7]) and one
study of these mice described plaque-like structures
[33]. However, mice that model aspects of Down’s syn-
drome, including triplication of the mouse APP gene, do
not develop AD-like amyloidosis [35]. Moreover, mice
that overexpress human presenilin with mutations linked
to FAD do not develop amyloid deposits [3, 45] nor do
mice with FAD knock-in mutations in murine presenilin
[15, 49]. Mice expressing 5-fold excess of wild-type
mouse APP also fail to produce amyloid deposits when
mated to mice expressing human PS1dE9 despite raising
the levels of MoAβ42 by more than 2 fold [21]. Thus,
the capacity of mouse Aβ to produce AD-like amyloid
pathology was thought to be limited.
Based on these foregoing observations, we hypothesized
that sequence variations within the mouse Aβ peptide, as
compared to human, may render the mouse peptide un-
able to form amyloid in vivo. However, because of the
complex influences of sequences within Aβ on cleavage by
α-, β-, and γ-secretase, it is difficult to pinpoint the basis
for the limited capacity of mouse Aβ to deposit. To facili-
tate more direct comparisons between mouse and human
Aβ peptides, we generated two strains of transgenic mice
that express a mouse APP695 transgene with mutations
linked to FAD, with one of these strains also co-expressing
human PS1dE9. Both strains of mice produced amyloid
deposits with morphologies that resemble human amyloid.
Interestingly, however, the distribution and texture of the
amyloid deposited in these two strains differs from what
we have seen in mice depositing human Aβ. Moreover,
the distribution and texture of the amyloid was different
depending upon whether human PS1dE9 was co-
expressed. These data are consistent with the notion that
sequence differences in deposited Aβ peptides and cleav-
age patterns by γ-secretase may produce distinct types of
amyloid pathology.
Materials and Methods
Generation of transgenic mice
We generated two different kinds of transgenic mice
overexpressing mouse Aβ. To enable direct comparison
to existing lines of humanized Aβ mice (e.g.
MoHuAPPswe/PS1dE9-Line 85 [24]), we produced mice
co-expressing mouse APP695 harboring the Swedish
(K595M/N596L) mutation and human PS1dE9 by co-
injecting the two transgenes, each driven by its own
prion promoter element [20], into fertilized embryos
from crosses of C3H/HeJ and C57BL/6J mice (C3/B6
F1). The two transgenes co-integrated and co-segregate
as a single locus. This new line of moAPP695swe/
PS1dE9 mice was designated D-943.
The other mouse APP transgenic mouse line we pro-
duced is similar to previously described inducible
MoHuAPPswe/ind (MoHuAPPsi) transgenic mice (line
107 x tTA) [23], except the Swedish (KM/NL) and Indiana
(V617F) mutations were incorporated into the mouse
APP695 cDNA (moAPPsi). To create this line of mice, we
co-injected the tet.PrP.moAPPsi construct with a construct
to express GFP in the skin (K14-GFP) to facilitate genotyp-
ing [42, 43]. This line of mice was generated in the FVB/NJ
strain (to enable visualization of the GFP). To induce trans-
gene expression, the moAPPsi-GFP mice were crossed to
CamKII-tTA mice [29] (congenic on the B6 background)
to produce trigenic mice that were B6/FVB F1. This com-
bination of strains is identical to that used in a recently
published study of tTA/MoHuAPPsi (line 107) mice [31].
This study also describes other lines of mice that have
not been previously published. These include a line of
mice that expressing a MoHuAPPswe/ind (MoHuAPPsi)
transgene under the transcriptional control of the
MoPrP.Xho vector. To facilitate genotyping, these mice
were created by co-injecting the MoPrP.MoHuAPPsi
construct with the K14-GFP construct. These constructs
were injected into C3B6 F1 mice and maintained in the
same background. The laboratory name for the line of
Fig. 1 Comparison of human and mouse Aβ sequences. The two primary sites of BACE1 cleavages, designated +1 and +11, are noted by
arrowheads above the sequences. The 3 sequence differences between human and mouse Aβ at residues 5, 10 and 13 are underlined in bold
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mice identified as expressing the transgene at useful
levels was MHSI-695-GFP (Additional file 1: Table S1).
Another line of mice described here for the first time is
a line created by co-injecting the tetPrP.MoHuAPPPsi
construct with the K14-GFP construct to produce mice
that could be easily genotyped. The line identified as be-
ing the most useful was designated MoHuAPPsi-GFP#2
(Additional file 1: Table S1). To induce transgene ex-
pression, this line of mice was crossed to CamKII-tTA
mice to produce trigenic mice.
In recognition that transgene names and laboratory
line designations can be complicated we have adopted a
strategy of simplified naming for the mice used in this
study in which the name includes information on the
transgene vector, the type of Aβ that is deposited, and
any co-injected genes (see Additional file 1: Table S1
and Results).
Other transgenic mice used in this study have been
described and fully characterized in earlier publications
including mice expressing MoHuAPP695swe (Lines C3.3
and Q2.2) [3, 24, 37]; mice expressing human PS1 har-
boring the FAD exon-9 deletion (PS1dE9; Line S9) [26];
and mice co-expressing both MoHuAPP695swe and
PS1dE9 (Line 85) [24]. All of these mice were main-
tained on a hybrid background by backcrossing to
C3HeJ × C57BL/6J F1 animals obtained from Jackson
Laboratories. The generation of the tTA/MoHuAPPsi
mice (line 107) has previously been described [23]. In
the present study we have used the line 107 mice that
have been backcrossed to C57BL/6J mice with B6
congenic CamKII-tTA mice [31]; bigenic male tTA/
MoHuAPPsi mice were mated with nontransgenic female
FVB/NJ mice to produce experimental animals [31]. All
procedures involving animal handling and processing were
approved by the University of Florida Institutional Animal
Care and Use Committee, following guidelines set forth by
the National Institutes of Health.
Sequential extraction of Aβ and ELISA
When a mouse was harvested, one hemisphere from each
mouse brain was frozen on dry-ice and kept at -80 °C, and
these tissues were used for ELISA analysis. The extraction
and ELISA methods used have been described previously
[25], with minor modification. Briefly, the hemi-brain was
seperated into forebrain and cerebellum and weighed. Ac-
cording to the brain weight, 6.67 volumes (in μl to mg of
brain) of cold Radio-immunoprecipitation Assay Buffer
(RIPA buffer; 50mM Tris-HCl, 150mM NaCl, 1 % Triton
X-100, 0.5 % Deoxycholate, 0.1 % SDS) with 1x protease
Inhibitor Cocktail Tablets Complete (Roche, Indianapolis,
IN, USA) was added. The tissue was homogenized by son-
ication on ice. Equal volumes of homogenate (500μl) were
loaded into ultracentrifuge tubes, then centrifuged at
100,000 x g for 1 hour at 4 °C. The supernatants were
collected, designated as RIPA soluble Aβ, and stored at
-80 °C. This fraction was also used for immunoblot ana-
lysis. The pellet was homogenized by sonication in 500 μl
of 2 % Sodium Dodecyl Sulfate (SDS) in water with prote-
ase inhibitor cocktail. The homogenate was loaded into an
ultracentrifuge tube and centrifuged at 100,000 x g for 1
hour at 4 °C. Same as above, the supernatant was collected
(SDS soluble) and stored at -80 °C. The pellet was saved
for formic acid extraction by sonication in 70 % formic
acid followed by centrifugation at 100,000 x g for 1 h at 4
°C. The supernatant (FA soluble) was collected and stored
at -80 °C. Before using, the formic acid extracts were neu-
tralized by diluting in 20 volumes of 1M Tris-Base, 0.5M
NaH2PO4. The samples were then assayed by sandwich
ELISA with end specific mAbs anti-Aβ42 (1-11-3 Aβx-42
specific, Covance Inc) and mAb 13.1.1 (Aβx-40 specific,
Mayo Clinic) for capture and horseradish peroxidase–con-
jugated mAb 4G8 (Covance Inc.) for detection.
Immunoblotting for transgene expression
Mice of each genotype were harvested at 2–3 months of
age for assessment of gene expression. Both hemi-brains
were frozen on dry ice and kept at -80 °C before using.
The frozen brains were sequentially extracted by RIPA,
SDS and formic acid as described above. Ten microliters
(10μl) of RIPA extracted homogenate (equal to ~50 μg
of total protein) were loaded onto 4–20 % Tris-Glycine
gel for SDS-PAGE. The following primary antibodies
were used: rabbit anti-PS1NT antibody against PS1
(1:5000, kind gift of Dr. Gopal Thinakaran, University of
Chicago, Chicago, IL, USA), 6E10 (mouse anti-human
Aβ monoclonal, 1:1500, Covance, NJ), 22C11 (mouse
anti-human and mouse APP N terminus monoclonal,
1:1000, EMD Millipore, MA) and human and mouse
SOD1 antibody (m/hSOD1, rabbit polyclonal, 1:2500)
[34]. The ECL images were visualized with a FluorChem
E imager (Protein Simple, Santa Clara, CA, USA).
Histology
The mice used for histology were euthanized by exsan-
guination and perfusion with phosphate buffered saline
(PBS) under isoflurane anesthesia. After the brain was
removed, one hemi-brain was frozen on dry-ice for bio-
chemical analysis as described above; the other hemi-
brain was immersion fixed in 4 % of paraformaldehyde
in PBS at 4 °C for 48 h, then was stored in PBS at 4 °C
until paraffin processing for sectioning. Tissue sections
of 5 μm or 10 μm thickness were used in histological
and immunological staining.
Hirano Silver Stain was done according to standard
protocol on 10-μm paraffin-embedded sections by Hirano’s
modification of the Bielschowsky method [51]. The slides
were scanned by Aperio® XT System (Leica Biosystems,
Buffalo Gove, IL, USA). Campbell-Switzer Silver Stain was
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done according to a detailed protocol provided by Dr.
Switzer (NeuroScience Associates, Knoxville, TN;
Campbell S, Switzer R, Martin T (1987) Alzheimer’s
plaques and tangles: a controlled and enhanced silver
staining method. Soc Neurosci Abst 13:678) [46].
Thioflavine S Staining followed the Guntern modification
of standard protocols [14]. Congo red staining was per-
formed according to standard techniques [24] with the
following modification. Deparaffinized slides with 5 μm
brain sections were counterstained in hematoxylin, then
immersed in Congo red solution (0.5 % Congo red, 2 %
NaCl in 80 % ethanol) for 10 min, rinsed and then
dehydrated and coverslipped. Slides were examined
under polarizing illumination for evidence of amyloid
deposition and images were captured with an Olympus
BX40 microscope.
Immunohistochemistry and immunofluorescence
staining followed standard protocols. Slides were depar-
affinized by oven heating followed by immersion in xy-
lene. After rehydration through graded alcohols into
water, the slides were steamed in citrate buffer for 30
min [2]. Nonspecific staining was blocked for 1 h with 3
% normal goat serum and 0.1 % Triton-X 100 in PBS.
Slides were then placed into primary antibody diluted in
PBS with 2 % normal goat serum and incubated over-
night at room temperature. Endogenous peroxidase ac-
tivity was quenched by incubation with 0.3 % hydrogen
peroxide in PBS for 10–20 min. After the excess primary
antibody was washed away with several changes of PBS,
slides were incubated with either the biotin-labeled sec-
ondary antibodies followed by diaminobenzidene (DAB)
visualization according to the protocols provided by the
supplier. The primary antibodies used are: 4G8 anti-
mouse or human Aβ monoclonal antibody (1:250, Cov-
ance, NJ); 6E10 anti-human Aβ monoclonal antibody
(1:250, Covance, NJ); rabbit monoclonal Aβ42 antibody
against both mouse and human Aβ 42 (1:500, Invitrogen);
mouse anti-GFAP antibody (1: 500, EMD Millipore, MA);
rabbit anti-ubiquitin antibody (1:1000, DAKO, CA). The
biotin-labeled secondary antibodies used were goat anti-
mouse or rabbit IgG (1:500, Vector Laboratories).
Image processing
The silver stained sections were scanned using the
Scanscope XT image scanner (Aperio, Vista, CA,
USA) and analyzed using the ImageScope program.
Amyloid plaques were digital extracted with the colocaliza-
tion V9 algorithm (Aperio). Images of the hippocampus, or
whole sagittal sections, were digitally cropped to generate
the final images.
Analysis of APP processing in cultured cells
Cell culture and transfection - Mouse neuroblastoma
N2a cells (ATCC, CCL-131) were cultured in 5 ml
medium containing DMEM/Opti-MEM with 5 % FBS in
60mm dishes at 5 % CO2. At 90 % confluence, 4 μg plas-
mid DNA (moAPPswe, moAPP-WT, MoHuAPPswe, and
MoHuAPP-WT, all in pEF-BOS expression vector [32])
was transfected with 8 μl of lipofectamine 2000 accord-
ing to the manufacturer’s protocol. After 24 h, the ori-
ginal medium was removed and 4ml fresh medium was
added. After another 24 h, the medium was collected for
Aβ assay.
Immunoprecipitation and mass spectrometry – 50 μl
of magnetic sheep-anti-mouse IgG beads (Invitrogen,
Grand Island, NY, USA) were incubated with 4.5 μg 4G8
antibody for 30 min at room temperature with constant
shaking. The beads were then washed with PBS and in-
cubated with 5 ml of conditioned medium from trans-
fected N2a cell to which 0.1 % Triton X-100 was added
for 30 min. Bound beads were washed sequentially with
0.1 % and 0.05 % octyl glucoside (Sigma-Aldrich, St.
Louis, MO) followed by water. Samples were eluted
with 10 μl 0.1 % trifluoroacetic acid (Thermo Scientific,
Rockford, IL, USA) in water. 2 μl of eluate was mixed with
an equal volume of saturated α-cyano-4-hydroxycinnamic
acid (CHCA) (Sigma-Aldrich) solution in 60 % aceto-
nitrile, 40 % methanol. 1 μl of sample mixture was loaded
on CHCA pretreated MSP 96 target plates (Bruker
Daltonics Inc., Billerica, MA, USA). The samples were
analyzed with a Bruker Microflex (Bruker Daltonics
Inc., Billerica, MA, USA) mass spectrometer.
Results
Prior studies of APP processing in murine cells have
demonstrated that murine BACE1 preferentially cleaves
wild-type mouse APP at the +11 residue of Aβ [6]. In
human cells, human WT APP is also preferentially
cleaved at residue +11, but the Swedish double muta-
tions in APP shift cleavage to the +1 residue [6]. To de-
termine whether introducing the Swedish mutations into
murine APP produces the same effects, we transfected
mouse N2a cells with expression vectors for moAPP695,
with and without the Swedish mutation, and analyzed
the Aβx-40 peptides produced by immunoprecipitation
and mass spectrometry (Fig. 2). For comparison we also
expressed WT and Swedish variants of the chimeric
MoHuAPP695 cDNAs used previously to produce trans-
genic mice [3]. Both the moAPP695 and MoHuAPP695
proteins with WT sequences produced primarily
Aβ11-40 (Fig. 2a and b), whereas both of these pro-
teins encoding the Swedish mutation [K595N,M596L]
produced primarily Aβ1-40 (Fig. 2a and b). Aβ42
levels were too low to quantify accurately in this system,
but there was trend of Aβ42 increasing in the N2a cells
expressing APP with Swedish mutation.
Satisfied that murine APP with the Swedish mutations
would enhance the production of Aβ1-40/42, we
Xu et al. Acta Neuropathologica Communications  (2015) 3:72 Page 4 of 15
proceeded to generate transgenic mice expressing mu-
tant murine APP695. Two constructs were generated;
one construct was moAPP695 with the Swedish muta-
tions (moAPPswe) and the other was moAPP695 with
the Swedish and Indiana mutations (moAPPsi). These
new lines of mice were compared to existing lines of
mice in our colony that express a humanized version of
moAPP695 (MoHuAPP), in which the Aβ sequence had
been modified to produce human Aβ [3]. These original
humanized APP mice were generated in this manner to
potentially avoid any effects that could arise from any
human APP specific activities of holo APP or shed APP
ectodomains. Thus, here we are essentially comparing
mice that over-express different variations of murine
APP that differ by AD mutation encoded and by
sequence of the Aβ peptides that would be generated.
To facilitate comparisons of any mice generated with
these constructs with existing lines of mice expressing
humanized APP constructs, we used two strategies to
produce transgenic mice. The moAPPswe constructs
were inserted in the MoPrP.Xho vector and co-injected
with MoPrP.Xho vectors encoding human PS1dE9 to
Fig. 2 Analysis of Aβ peptides produced by mouse N2a cells transiently expressing mouse and MoHu chimeric APP genes. a Examples of mass
spectrometry data from the analysis of cell culture medium of mouse N2a cells transiently transfected with expression plasmids encoding
moAPP-WT, moAPPswe, MoHuAPP-WT, and MoHuAPPswe. The Aβ in the medium was immunoprecipitated with the monoclonal antibody 4G8
and then analyzed by mass spectrometry. The positions of mouse and human Aβ40 (mAβ40 and hAβ40) are noted on the spectrum traces. b
Analysis of data from repeated experiments (n = 3) demonstrated that the Swedish mutations in mouse APP shift cleavage to produce a greater
amount of Aβ1-40 over Aβ11-40. Standard deviation (SD) was shown at the error bars
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mimic previously described MoHuAPPswe/PS1dE9-Line
85 mice [24]. The moAPPsi cDNAs were inserted into
tetPrP.Xho vectors to mimic previously described
tetPrP.MoHuAPPsi-Line 107 mice [23]. Founders for
each of the transgene injections were produced and, as
described below, we identified one line of mice for each
that expressed total APP levels that were comparable to
existing lines of MoHuAPP mice. Because of the compli-
cated nomenclature that arises in generating identifiers for
different lines of mice, for this paper we identify the mice
with short-hand abbreviations for vector used (PrP or tet),
sequence of Aβ produced (mo or Hu), and co-expressed
transgenes (see below) (Additional file 1: Table S1).
Analysis of moAPPswe and moAPPsi expression in
transgenic mice
A line of moAPPswe/PS1dE9 mice designated as line D-
943 (which we identify from here on as PrP.MoAβ/PS1)
(Additional file 1: Table S1) was found to express total
APP (transgene plus endogenous) at levels comparable
to the previously described MoHuAPPswe/PS1dE9-Line
85 mice [24] (from here on identified as PrP.HuAβ/PS1)
(Fig. 3). Brain homogenates of 3 different PrP.MoAβ/
PS1 mice were compared to brain homogenates of 3 dif-
ferent PrP.HuAβ/PS1 mice by immunoblot with anti-
bodies to human presenilin, the monoclonal antibody
6E10 (prefers human APP/Aβ), the monoclonal antibody
22C11 (recognizes an N-terminal epitope that is shared
by all APP constructs used), and SOD1 (a loading con-
trol). The immunoblots probed with 22C11 demon-
strated similar levels of total APP in the PrP.MoAβ/PS1
and PrP.HuAβ/PS1 mice (Fig. 3). Similarly, the levels of
human PS1dE9 protein were similar in the two lines of
mice (Fig. 3). The APP expressed in PrP.HuAβ/PS1 mice
was much more reactive to the monoclonal antibody
6E10 as expected. Immunoblots probed with the SOD1
antibody demonstrated equal loading (Fig. 3). These data
demonstrate that our newly developed PrP.MoAβ/PS1
mice express the transgene at levels that are similar to
our previously characterized PrP.HuAβ/PS1 mice [24].
In producing the tetPrP.moAPPsi mice, we employed a
strategy in which we co-injected the APP transgene with
a transgene construct that encodes green fluorescent
protein (GFP) under the transcriptional control of the
K14 promoter (see Methods). We have recently used this
strategy in producing a series of transgenic mice that ex-
press N-terminal fragments of mutant huntingtin [42, 43].
Expression of the GFP in skin provides an easy marker to
identify transgenic animals and lowers the cost of main-
taining the lines of mice. To induce expression, the
tetPrP.moAPPsi mice were crossed to mice expressing the
tetracycline-transactivator construct under the transcrip-
tional control of the CamKII promoter in a strategy iden-
tical to what was previously used to express MoHuAPPsi
[23]. The levels of total APP (detected with monoclonal
antibody 22C11) in bigenic tTA/moAPPsi [hereafter iden-
tified as tet.MoAβ(GFP)] mice (Additional file 1: Figure
S1, lane 5 and 6) were similar to that of the PrP.MoAβ/
PS1 and PrP.HuAβ/PS1 mice, but much lower than two
different lines of tet.HuAβ mce (bigenic for CamKII-tTA
and tet.MoHuAPPsi; see Additional file 1: Table S1) that
express humanized APP that we currently have in our
colony. One of these lines of tet.HuAβ mice, desig-
nated line 107, has previously been described [23]
[hereafter designated tet.HuAβ(107)], the other line,
carrying the laboratory name tetMoHuAPPsi-GFP#2
[hereafter identified as tet.HuAβ(GFP)], has not been
described previously and is a new line of mice that
was made by co-injection of the K14-GFP vector. In
our colony, there is also a line of mice that expresses
MoHuAPPsi via the constitutive MoPrP.Xho vector
(also co-injected with K14-GFP, carrying the laboratory
name of MHSI-695-GFP) that has not been previously
described [hereafter designated PrP.HuAβ(GFP)]. Fortu-
nately, the levels of total APP in the brains of bigenic tet.-
MoAβ mice were similar to the levels in PrP.HuAβ(GFP)
mice (Additional file 1: Figure S1), providing a line of mice
that could be directly compared to the tet.MoAβ mice.
Collectively, these lines of mice provide a basis for com-
parison of amyloid pathology in mice that produce mouse
or human Aβ while controlling for the effects of co-
Fig. 3 Comparison of APP and PS1 expression levels in PrP.MoAβ/
PS1 and PrP.HuAβ/PS1 mice. The brains of 2 non-transgenic (age
1.6–2.4 months) and 3 each PrP.MoAβ/PS1 (Line D-943; aged 2.5–3.3
months) and PrP.HuAβ/PS1 (Line 85, aged 1.6–2.4 months) mice
were homogenized in RIPA buffer, the supernatants were analyzed
by immunoblotting 4–20% SDS-PAGE gels with antibodies to PS1
(1:5000, top row), human APP (mAb 6E10, 1:1500, second row), total
APP (mAb 22C11, 1:1000, third row), or mouse SOD1 (1:2500, fourth
row). The mouse SOD1 immunoblot served as a loading control. The
levels of PS1dE9 and total APP were similar in the two lines of mice.
Each lane contains 50 μg of total protein
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expressed human PS1dE9 and the co-injection of
K14-GFP vectors to mark transgenic animals.
Analysis of amyloid deposition in the PrP.MoAβ/PS1 and
PrP.HuAβ/PS1 mice
Our first observation was that the age at which amyloid
deposits first appear in the PrP.MoAβ/PS1 mice was
much later than that of the PrP.HuAβ/PS1 mice. Amyl-
oid deposits first appear in the hippocampus of
PrP.HuAβ/PS1 mice at about 6 months of age and are
readily visible in silver stains by 8 months of age (Fig. 4).
Amyloid deposits were first visible in the hippocampus
of PrP.MoAβ/PS1 mice at 13 months old (1 out of 4 ob-
served), but then became consistently visible in 18 month
old animals. The frequency of deposits was slightly higher
in 24 month old mice, visible in the corpus callosum and
the area adjacent to the hippocampal fissure (Fig. 4, ar-
rows). Still, the amyloid burden in the hippocampus of 24
month old PrP.MoAβ/PS1 mice was considerably lower
than that of 8 month old PrP.HuAβ/PS1 mice (Fig. 4).
In the brains of 24 month old PrP.MoAβ/PS1 mice we
observed amyloid deposits concentrated in the subpial
layers of the cortex and cerebellum, and the white matter
tracts of the corpus callosum (Additional file 1: Figure S2
and S3). By contrast, as previously reported [24], the pla-
ques in the PrP.HuAβ/PS1 mice were distributed through-
out the cortex and hippocampus. In the cerebellum of
PrP.HuAβ/PS1, the amyloid distribution was more similar
to that of the PrP.MoAβ/PS1 mice, being concentrated in
subpial layers (Additional file 1: Figure S2 and S3). Thus,
in the PrP.MoAβ/PS1 mice, both the age of onset and the
pattern of deposition of amyloid differed from that seen in
PrP.HuAβ/PS1 mice.
At the microscopic level, the morphology of amyloid
deposits in the PrP.MoAβ/PS1 and PrP.HuAβ/PS1 mice
were similar (Fig. 5): both showed GFAP immunoreactive
astrocytes in close proximity to the plaques, both dis-
played a compact morphology, both stain with thioflavin S
(Fig. 5), and show congo red birefringence and fluores-
cence (Additional file 1: Figure S4). Immunostaining with
Fig. 4 Distribution of amyloid deposition in PrP.MoAβ/PS1 and PrP.HuAβ/PS1 mice. Representative images of the hippocampus from tissue
sections stained by Campbell-Switzer silver stain are shown. The approximate age of the animal at the time of sacrifice is shown. The amyloid
appears as the dark black material. The images shown are representative of images from an analysis of at least 3 animals at each age and each
genotype with at least 6 individual tissue sections taken from similar levels for each animal
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antibodies to Aβ (monoclonal Ab 4G8 and Aβ42 specific)
demonstrated that dense cored plaques in the PrP.MoAβ/
PS1 were similar to deposits in PrP.HuAβ/PS1 mice
(Fig. 5). There was no remarkable staining with Aβ42
specific antibodies within cell bodies in either of these
lines of mice (not shown). Similarly, immunostaining
with ubiquitin revealed neuritic pathology in close
proximity to the deposits in PrP.MoAβ/PS1 mice
(Fig. 5). Similar to what we have previously described
for the PrP.HuAβ/PS1 mice [50], there was no evi-
dence of tau neuritic pathology or obvious neuronal
loss in hippocampal structures in the PrP.MoAβ/PS1
mice (data not shown).
Comparison of amyloid deposition in tet.MoAβ(GFP),
tet.HuAβ(107), and tet.HuAβ(GFP) mice
The distribution of the amyloid deposits in the tet.-
MoAβ(GFP) contrasted starkly to that of the PrP.MoAβ/
PS1 mice. The tet.MoAβ(GFP) mice developed deposits
primarily throughout the parenchyma of the rostral cor-
tex with lesser amounts of amyloid in the hippocampus
(Fig. 6 and Additional file 1: Figure S5). Because the
CamKII promoter drives expression of tTA and the
responsive tet.PrP-moAPPsi transgene, primarily in the
forebrain [23], the absence of amyloid pathology in the
cerebellum is expected in these mice. Somewhat surpris-
ingly, the level of amyloid in hippocampus in 15–18 month
Fig. 5 Histologic comparison of amyloid plaque morphology in PrP.MoAβ/PS1 and PrP.HuAβ/PS1 mice. Representative images of cortical amyloid
plaques in tissue sections stained with antibodies to GFAP, Aβ (mAb 4G8 and rAb Aβ42) and ubiquitin, and by Campbell-Switzer silver stain or
Thioflavin-S staining. The images shown are representative of an analysis of at least 3 animals at each age and each genotype with at
least 6 individual tissue sections taken from similar levels for each animal. All the images shown were obtained at the same magnification
(40x) and digitally cropped
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old tet.MoAβ(GFP) mice was variable (Fig. 6; undetectable
in the example shown), but by 24 months of age hippo-
campal deposits were relatively abundant (Additional file 1:
Figure S6). The deposited amyloid in the tet.MoAβ (GFP)
mice was much more diffuse; most of these deposits were
not stained with Thioflavin-S, and those that did show
some staining were only faintly fluorescent (Fig. 6). The
amyloid deposited in these mice did not produce birefrin-
gence with congo red (data not shown). Still, these diffuse
deposits showed GFAP reactive astrocytes in close proxim-
ity and evidence of ubiquitin positive neuritic structures
(Fig. 6). Overall, the data demonstrate abundant amyloid
deposition in the mice, but the amyloid largely appeared to
be diffuse deposits with little or no cored deposits.
Given the rather unique appearance of the amyloid
pathology in the tet.MoAβ(GFP) mice, we provide here a
comparison to two strains of mice that deposit HuAβ,
using tet-regulated vectors and CamKII-tTA drivers to
expressed humanized APP. One of these lines of mice is
a previously described line that designated line 107
[tet.HuAβ(107)] [23]. The other line is a line devel-
oped more recently in which the tet-MoHuAPPsi
transgene was co-injected with the K14-GFP construct
[tet.HuAβ(GFP)], essentially a comparable strategy to
what was used to generate the tet.MoAβ(GFP) mice.
These two lines of tet.HuAβ mice consistently developed
cored neuritic amyloid plaque pathology in both the
cortex and hippocampus at about the same time (see
Fig. 6 Analysis of amyloid distribution and morphology in tet.MoAβ(GFP) mice. The overall distribution of deposited amyloid is shown by digital
extraction of staining by Cambell-Switzer silver staining. Additional representative images of cortical amyloid in tissue sections stained with antibodies
to GFAP, Aβ (mAb 4G8 and rAb Aβ42) and ubiquitin, and by Campbell-Switzer silver stain or Thioflavin-S staining. The images shown are representative
of images from an analysis of at least 3 animals at each age and each genotype with at least 6 individual tissue sections taken from similar levels for
each animal. The example of Thioflavin-S staining of the tet.MoAβ(GFP) tissue represents the maximal fluorescent intensity that was observed. All the
images were shown at the same amplification after cropping from 40x microscope images
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Additional file 1: Figure S5). In both of these models, there
was little evidence of amyloid deposition around blood
vessels supplying the cortical parenchyma. The majority of
amyloid that one could potentially describe as vascular
was restricted to the subpial layers (Additional file 1:
Figure S5). Thus, in two distinct lines of tet.HuAβ
mice, the amyloid pathology that developed was quite
distinct from that of the tet-MoAβ mice.
To determine how the co-expression of PS1dE9 influ-
enced the morphology and distribution of amyloid, we
examined the amyloid pathology in mice that express
MoHuAPPsi that were made by co-injection with K14-
GFP [PrP.HuAβ(GFP)]. The APP gene expressed in
these mice is identical to what is expressed in the
tet.HuAβ(107) and tet.HuAβ(GFP) mice. Amyloid path-
ology found in these PrP.HuAβ(GFP) mice was similar
to that of the PrP.HuAβ/PS1 mice (Additional file 1: Figure
S7). The only mentionable difference was that the level of
diffuse amyloid pathology in the PrP.HuAβ(GFP) mice was
higher than that of the PrP.HuAβ/PS1 mice. Additionally,
similar to the PrP.MoAβ/PS1 and PrP.HuAβ/PS1mice,
the PrP.HuAβ(GFP) mice developed amyloid pathology
in the choroid plexus bordering the hippocampus
(Additional file 1: Figure S7).
Analysis of Aβ peptides deposited in the brains of
MoHuAPP and moAPP transgenic mice
Analysis of Aβ peptides deposited in the brains of the
different transgenic mice by ELISA, with antibodies spe-
cific to Aβ40 and 42, produced data that paralleled the
neuropathologic analyses and revealed an intriguing dif-
ference between the HuAβ and MoAβ depositing mice.
As expected from the neuropathological data, the levels
of insoluble Aβ increased as the animals aged, with the
levels of insoluble Aβ in the brains of the PrP.HuAβ/PS1
mice (both SDS and formic acid extractable) being
higher than that of the PrP.MoAβ/PS1 mice (Additional
file 1: Figure S8A). Unexpectedly, there was a stark differ-
ence in the ratio of insoluble Aβ40 to Aβ42 in the brains
of these mice. In the PrP.HuAβ/PS1 mice, the ratio of
Aβ42 to 40 ranged from 2:1 to 10:1 (Additional file 1:
Figure S8B), whereas in the forebrains of the
PrP.MoAβ/PS1 mice the ratio ranged from 10:1 to
20:1 (Additional file 1: Figure S8B). These data indicate
that murine Aβ40 is far less prone to co-aggregate with
Aβ42 than the human peptides.
Another striking feature observed in our ELISA ana-
lysis was that almost all of the Aβ in the brains of the
tet.MoAβ(GFP) mice was soluble in SDS with very low
levels in the formic acid fraction (Additional file 1: Figure
S9); data that are consistent with the diffuse morphology
of the amyloid deposits in this line of mice. The ratio of
Aβ42 to 40 in the SDS-soluble fraction skyrocketed as the
mice aged (Additional file 1: Figure S9), indicating that the
vast majority of the deposited peptide was Aβ42. Thus, in
both of our strains of mice that developed mouse Aβ
amyloid, the primary deposited peptide was Aβ42.
Cerebellar amyloid
Cerebellar amyloid deposits in the PrP.HuAβ/PS1 mice
were observed when these mice were first analyzed more
than 10 years ago [23], but the significance of such path-
ology was enigmatic and thus not fully described. The first
mice that co-expressed humanized APP (MoHuAPPswe)
and PS1dE9 mice were produced by crossing mice that in-
dependently expressed the genes, and in a re-examination
of these animals we document that the frequency of cere-
bellar amyloid deposits was very low (Table 1). A similarly
low frequency of cerebellar amyloid was observed with a
second line of MoHuAPPswe mice (line Q2-2) that was
crossed to the PS1dE9 mice (Table 1). Here, we document
the features of cerebellar amyloid in the PrP.HuAβ/PS1
and the PrP.MoAβ/PS1 mice made by co-injecting the
transgenes.
Cerebellar amyloid occurs in two distinct lines of
PrP.HuAβ/PS1 mice; the widely-used Line 85 mice and
a sister line mice designated Line 57 [20] (Table 1). Al-
though the amyloid plaques in the cerebellum of the
PrP.HuAβ/PS1 (Line 85) mice were generally small, Hir-
ano and Campbell-Switzer silver stains revealed deposits
that were morphologically similar to deposits observed
in forebrain structures (Fig. 7). For example, amyloid de-
posits in both the grey and white matter of the cerebel-
lum of these mice appeared as compact deposits
(Fig. 7a–f ). Similar deposits were observed in the
PrP.MoAβ/PS1 mice (Fig. 7), but here the deposits were
small, very compact structures that were more frequent
in the white matter tracts (Fig. 7g–i). Previous studies of
patients with the PS1dE9 mutation have described non-
neuritic amyloid plaques in the cerebellum [9, 47, 48].
We have previously described the utility of ubiquitin im-
munostaining as a means to identify neuritic plaques
[22], and we used this approach to determine whether
the cerebellar amyloid deposits in these mice showed
neuritic profile. High power images of deposits in cere-
bellum reveal eosinophilic cores of amyloid surrounded
Table 1 Comparison of the frequency of cerebellar amyloid
deposits among the different lines of transgenic mice analyzed
Aβ Human Mouse
Transgenes PrP.HuAβ/PS1 PrP.HuAβ PrP.MoAβ/PS1
Line 85 57 C3.3xS9 Q2.2xS9 MHSI-695 D-943
Age (mo)* 16 21 18 22 20 24
Hippocampus +++ +++ +++ +++ +++ ++
Cerebellum +++ +++ + - + ++
+: 1–5 plaques, ++: 6–20 plaques, +++: >20 plaques
*Age analyzed
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by ubiquitin immunoreactive neurites (Additional file 1:
Figure S10). Analysis of the Aβ peptides deposited in the
cerebellum of these mice demonstrated that both Aβ42
and 40 are deposited in the cerebellum of the
PrP.HuAβ/PS1 (line 85) mice, ratio ranges from 5:1 to
10:1. In the PrP.MoAβ/PS1 mice the ratio was much
higher, all greater than 15:1 (see Additional file 1: Figure
S8B). In general, the architecture of cerebellar amyloid
plaques in the PrP.HuAβ/PS1 and PrP.MoAβ/PS1 mice
was very similar to that of deposits in the hippocampus
and cortex, although deposits in the cerebellum of each
line were generally smaller than the deposits in the fore-
brains of the same animal.
Discussion
Our findings provide the first examples of amyloid path-
ology formed by rodent Aβ peptides. Unlike other mam-
malian species, aged rodents have not been reported to
develop Aβ deposits unless they express APP genes en-
coding human Aβ sequences [12, 38] or harbor modified
APP genes in which the exon encoding the Aβ domain
has been modified to encode human Aβ [10, 36]. The
lack of amyloid pathology in aged rodents cannot be
fully explained by the inherent abilities of mouse and
human Aβ peptides to form fibrillar aggregates since
both peptides show similar propensity to aggregate in
vitro [11]. However, it is now well recognized that the
processing of APP by its three secretases is heavily influ-
enced by the sequence of the peptide and adjacent se-
quences in the APP holoprotein (for review see [8, 16]),
with the processing by BACE1 having a major influence
on whether Aβ1-40/42 or 11–40/42 is generated [6]. For
wild-type moAPP, cleavage by murine BACE favors the
production of the non-amyloidogenic Aβ11-40/42 pep-
tides. Thus, whether murine Aβ1-40/42 is really incap-
able of fibrillogenesis had not rigorously been tested
in vivo. Our study now provides the rigorous test by
introducing moAPP transgenes harboring mutations
linked to FAD that shift cleavage of APP to favor the
production of moAβ1-40/42. Our findings indicate the
moAβ is fully capable of forming both diffuse and com-
pact amyloid plaques in vivo. For reasons that we have
yet to elucidate, the morphology of the deposited amyl-
oid in these models was heavily influenced by the mode
of transgene expression and whether human PS1dE9
was co-expressed. Nevertheless, the data provide the
Fig. 7 The morphology of amyloid plaques in the cerebellum of D-943 and Line 85 mice. a–c Representative images of cerebellum stained by
Hirano silver staining. d–i Representative images stained by Campbell-Switzer silver staining. a–f PrP.HuAβ/PS1 mice (line 85); g–i PrP.MoAβ/PS1
mice. a, d and g 10x objective; b, c, e, f, h and i) 40x objective. b, e and h) Cerebellar grey matter plaques; c, f and i) Cerebellar white matter plaques
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first definitive proof that Aβ peptides of murine amino
acid sequence can produce amyloid plaques that are
morphologically similar to human amyloid deposits.
The present report also documents, for the first time,
the frequency and severity of cerebellar amyloid deposits
in the mice that co-express mutant APP and mutant
PS1. In the initial iterations of bigenic APP/PS1dE9
mice, generated by crossing 2 independent lines of mice,
cerebellar amyloid deposits were inconsistently observed,
and present at a low frequency when observed (see
Table 1). However, in the more commonly used bigenic
APPswe/PS1dE9 mice, generated by co-injection of the
transgenes [20, 24], the levels of cerebellar amyloid are
considerably higher. The more often used APPswe/
PS1dE9 mice Line 85 mice (Jax Strains 005864 and
004462) were created at the same time as a second line,
designated line 57. Mice from line 57 were first de-
scribed by Jankowsky et al. [20], whereas mice from Line
85, which initially bred poorly, were not described until
later [24]. For enigmatic reasons, the Line 85 mice
emerged as the more used line mice that is deposited in
the Jackson Laboratories. We have routinely aged mice
from Line 85 out to advanced ages and have never ob-
served obvious gait abnormalities. However, mice of this
line have been tested on the rotarod device and have
been reported to show deficits [40]. Thus, the presence
of amyloid pathology in the cerebellum of the APPswe/
PS1dE9 mice may produce moderate deficits in motor
performance.
Although cerebellar amyloid pathology is rare in spor-
adic AD, studies of Finnish patients with the PS1dE9
mutation have documented frequent amyloid deposits in
the cerebellum [47]. This unusual pathology correlated
to unusual symptoms of paraparesis in this pedigree [9].
In this same pedigree, pathologic descriptions of patients
with the PS1dE9 mutation demonstrated unusual amyl-
oid plaque pathology with structures termed cotton wool
plaques along with abundant non-cored senile plaques
in the cerebral cortex [9, 47]. Thus, the presence of cere-
bellar amyloid pathology in mice that co-express mutant
APP and PS1dE9 may represent a partial reproduction
of the human pathology. However, we also observed
amyloid pathology in the pia surrounding the cerebellum
of PrP.HuAβ(GFP) mice, which do not express PS1dE9.
Moreover, McGowen et al observed cerebellar amyloid
in mice that express fusion proteins of Bri-Aβ42 via the
MoPrP.Xho vector [30]. Thus, there may also be influ-
ences of the vector used to produce the transgenic ex-
pression on the distribution of amyloid deposition.
Presenilins are integral components of the γ-secretase
complex, which is one of two primary enzymes involved
in cleaving APP to produce Aβ40 and Aβ42 [for review
see [8, 16]. In regard to the generation of Aβ peptide,
the major consequence of AD-linked mutations in PS1
and PS2 on APP processing is to shift the processivity of
γ-secretase cleavage such that more Aβ42 is produced
relative to shorter Aβ peptides such as Aβ38 (for review
see [8, 16]). This shift in abundance promotes the depos-
ition of Aβ40 and 42 into senile plaques. Multiple la-
boratories have demonstrated that the PS1dE9 mutation
was among those that produce the most robust increase
in the production of Aβ42 [5, 41]. Additionally, when
mutant human PS1dE9 is overexpressed, it competes for
other cofactors of γ-secretase (nicastrin, Pen2, Aph1)
causing a displacement of the endogenous PS1 from this
complex [26, 44]. Thus, we can reasonably expect mice
that co-express APPswe with PS1dE9 may produce a
slightly different spectrum of Aβ peptides than mice in
which γ-secretase contains only endogenous mouse PS1.
This difference in the spectrum of peptides produced
could modulate the location and architecture of depos-
ited amyloid.
Both of our lines of mice depositing MoAβ peptides
displayed novel patterns of amyloid deposition and dis-
tinct plaque morphologies (Table 2). Notably, regardless
of distribution or morphology, all types of deposits were
found to include ubiquitin-immunoreactive profiles indi-
cative of neuritic pathology. Collectively, we compare 3
lines of mice that use the MoPrP.Xho vectors to 3 lines
that use CamKII-tTA + tetPrP.Xho vectors (Table 2).
The PrP.HuAβ/PS1 (Line 85) mice are representative of
all lines of mice expressing MoHuAPPswe and PS1dE9,
developing cored amyloid deposits in both the cortex
and hippocampus that show a wide distribution in the
parenchyma (Table 2). The PrP.MoAβ/PS1 mice devel-
oped amyloid deposits in the meninges surrounding the
cortex and cerebellum with additional deposits in the
white-matter tracts. Since the identical vector
(MoPrP.Xho) was used in generating these lines of mice,
the difference in patterns of deposition cannot be easily
explained by transgene expression patterns. Although we
cannot rule out the possibility that the site of transgene
integration modulates expression levels in some population
of cells to produce these distinct patterns of deposition, the
simplest explanation is that the amino acid sequence differ-
ences between human and mouse Aβ, in some manner,
modulate the distribution of amyloid plaques.
The strikingly distinct pattern of deposition and
morphology of deposits in the tet.MoAβ(GFP) mice is
also remarkable. The distribution of the moAβ deposits
shifts to the parenchyma of the cortex, and the morph-
ology is quite distinct (Table 2). The tet.MoAβ(GFP)
mice stand alone as the only one in which the amyloid
deposits are primarily diffuse. However, we did observe
that the PrP.HuAβ(GFP) mice, which also lack co-
expressed PS1dE9, displayed a higher level of diffuse
amyloid, particularly in the cortex. From these direct
comparisons, it would seem that the amino acid
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sequence of the Aβ peptides that are deposited may have
some influence on the morphology of deposited amyloid,
but the co-expression of human PS1dE9 may also have
some influence.
The unexpected question is: Why do the PrP.MoAβ/
PS1 and tet.MoAβ(GFP) mice differ in both distribution
and morphology of deposition? The two vectors systems
used will be expressed in different, but overlapping pop-
ulations of neurons. MoPrP.Xho is expressed in all neu-
rons and astrocytes [4, 27] whereas the CamKII-tTA is
expressed only in forebrain neurons [29]. The final proc-
essed Aβ derivatives of the APP transgenes in these mice
are expected to have identical sequences. It is possible
that the co-expression of PS1dE9 changes the mixture of
Aβ1-40/42 and other smaller Aβ peptide derivatives,
such as Aβ38, relative to the population of Aβ deriva-
tives produced by γ-secretase containing endogenous
presenilin, and that these differences in relative levels of
the different derivatives underlie our observations. How-
ever, these new questions that arise from our findings do
not diminish the overall conclusions of our study, which
demonstrates for the first time that murine Aβ peptides
possess the capacity to form amyloid deposits in vivo.
The degree to which murine Aβ deposits may influence
cognitive behavior in mice is a topic for future study, but
the late onset and distribution of amyloid in the
PrP.MoAβ/PS1 mice is not indicative of a high probability
of having a major impact on cognition. The tet.MoAβ(GFP)
mice may offer an opportunity to examine the effects
of diffusely deposited Aβ42 on cognitive function, but
again the late onset of deposition creates challenges
in assessing cognitive behavior.
Conclusions
In summary, we describe, for the first time, mice that
develop Alzheimer-type amyloidosis composed of mur-
ine Aβ peptides. Our findings provide a benchmark of
comparison to the pathology induced in nontransgenic
rodents challenged by environmental or dietary manipu-
lations. Similar to mice expressing humanized APP
genes and humans themselves, mice deposit murine Aβ
in extracellular deposits that are morphologically similar
to what has been described in humans (diffuse or com-
pact). Although the age to deposit in the PP.MoAβ/PS1
mice was considerably later than that of the PrP.HuAβ/
PS1 mice, despite comparable levels of expression, the
first deposits in tet.MoAβ(GFP) mice were no later than
that of mice expressing humanized APP transgenes at
comparable levels (Table 2). Thus, we do not observe
consistent differences in the rates of deposition between
human and mouse Aβ. Overall, we conclude that mouse
and human Aβ42 peptides have similar capacities to
form amyloid in vivo with the sequence differences, by
some manner, influencing where the amyloid deposits
form and their morphological architecture.
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Aβ sequence Human Mouse Human Human Mouse Human
APP expression level ++ ++ ++ +++ ++ +++
Age pathology first observed (months) ~6 ~13 ~12 ~3 ~13 ~6
Cortical Pathology P P/M/WM P P P P
C C C/D C D C/D
Hippocampal Pathology P P/M/WM P/M P P P
C C C/D C D C
(very late)
Cerebellar Pathology P/M/WM P/M/WM P/M - - -
C C C
P Parenchymal, M Meningeal, WM White matter tract distribution, C Cored, D Diffuse morphology
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